Aliskiren (Rasilez▼): risk of cardiovascular and renal adverse reactions

New contraindications and warnings for combination of aliskiren (Rasilez) with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).